AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
AstraZeneca's breast cancer drug combination fails in late-stage trial
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer.
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Astrazeneca (AZN) closed at $79.31, indicating a -0.35% shift from the previous trading day.
AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
The FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on data from the phase III DUO-E study.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism.
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then.
AstraZeneca: ASCO feedback positive
Reaction to AstraZeneca PLC (LSE:AZN)'s presentations at the annual American Society of Clinical Oncology conference was broadly positive following of sessions with analysts and clinicians. Eye-catching was the claim around Tagrisso, which was hailed as "practice changing" when administered to lung cancer with a certain mutation of the disease.
